Spadaro Anthony, Faude Sophia, Perrone Jeanmarie, Thakrar Ashish P, Lowenstein Margaret, Delgado M Kit, Kilaru Austin S
Center for Addiction Medicine and Policy Perelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania USA.
Center for Emergency Care Policy and Research Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania USA.
J Am Coll Emerg Physicians Open. 2023 Jan 23;4(1):e12880. doi: 10.1002/emp2.12880. eCollection 2023 Feb.
Buprenorphine is a highly effective medication for the treatment of opioid use disorder, but it can cause precipitated withdrawal (PW) from opioids. Incidence, risk factors, and best approaches to management of PW are not well understood. Our objective was to describe adverse outcomes after buprenorphine administration among emergency department (ED) patients and assess whether they met the criteria for PW.
This study is a case series using retrospective chart review in a convenience sample of patients from 3 hospitals in an urban academic health system. This study included patients who were reported by clinicians as potential cases of PW. Relevant clinical data were abstracted from the electronic health record using a structured retrospective chart review instrument.
A total of 13 cases were included and classified into the following 3 categories: (1) PW after buprenorphine administration consistent with guidelines (n = 5), (2) PW after deviating from guidelines (n = 4), and (3) protracted opioid withdrawal with no increase in Clinical Opiate Withdrawal Scale score (n = 4). A total of 11 patients had urine drug testing positive for fentanyl, and 11 patients received additional doses of buprenorphine for symptom management. Of the patients, 5 had self-directed hospital discharges, and 6 were ultimately discharged with prescriptions for buprenorphine.
Cases of adverse outcomes after buprenorphine administration in the ED and hospital meet criteria for PW, although some cases may have represented protracted opioid withdrawal. Further investigation into the incidence, risk factors, management of PW as well as patient perspectives is needed to expand and sustain the use of buprenorphine in EDs and hospitals.
丁丙诺啡是治疗阿片类物质使用障碍的一种高效药物,但它可引发阿片类物质戒断反应(PW)。PW的发生率、危险因素及最佳处理方法尚未完全明确。我们的目的是描述急诊科(ED)患者使用丁丙诺啡后的不良结局,并评估这些结局是否符合PW的标准。
本研究是一项病例系列研究,采用回顾性病历审查方法,纳入城市学术医疗系统中3家医院的便利样本患者。本研究纳入了临床医生报告的潜在PW病例。使用结构化回顾性病历审查工具从电子健康记录中提取相关临床数据。
共纳入13例病例,分为以下3类:(1)使用丁丙诺啡后出现符合指南的PW(n = 5),(2)使用丁丙诺啡后出现不符合指南的PW(n = 4),以及(3)阿片类物质戒断反应延长但临床阿片类物质戒断量表评分未增加(n = 4)。共有11例患者尿液药物检测芬太尼呈阳性,11例患者接受了额外剂量的丁丙诺啡以控制症状。其中,5例患者自行出院,6例最终出院时开具了丁丙诺啡处方。
急诊科和医院中使用丁丙诺啡后出现不良结局的病例符合PW的标准,尽管有些病例可能表现为阿片类物质戒断反应延长。需要进一步调查PW的发生率、危险因素、处理方法以及患者的观点,以扩大和维持丁丙诺啡在急诊科和医院的使用。